Bringing new drugs to untreatable diseases

<p><span data-contrast="auto">In the</span><a href= "https://www.ddw-online.com/t/in-conversation-series/"><em><span data-contrast="auto"> In Conversation With</span></em> </a><span data-contrast= "auto">series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. </span> <span data-ccp-props= "{"201341983":0,"335559739":160,"335559740":259}"> </span></p> <p><span data-contrast="auto">In this latest episode, DDW's Megan Thomas is</span> in conversation with Dr Simon Fricker, who just last year was made Chief Development Officer of PepperBio to support the company’s next phase of growth and guide the strategic expansion of Pepper’s oncology pipeline.</p> <p>Over the course of his career, including eight years as a distinguished scientific fellow at Genzyme/Sanofi, Dr. Fricker worked on three approved drugs: Paraplatin, Fosrenol, and Mozobil. Dr. Fricker was a founder of Canadian biopharma company AnorMED, acquired by Genzyme, and awarded the Queen’s Award for Technology for his participation in the development of the anticancer drug Paraplatin.</p>